A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors.
Takafumi Koyama, Kan Yonemori, Jun Sato...
https://pubmed.ncbi.nlm.nih.gov/41979863/Actively Recruiting
Led by Toray Industries, Inc · Updated on 2026-10-08
146
Participants Needed
27
Research Sites
N/A
Total Duration
Researchers are evaluating the combination of TRK-950 with ramucirumab and paclitaxel compared to ramucirumab and paclitaxel alone in people with gastric or gastro-esophageal junction adenocarcinoma. The study aims to assess the effectiveness, safety, best dose, and development of anti-drug and neutralizing antibodies of TRK-950. This is a phase 2 randomized trial focused on progression-free survival as the main outcome, along with other measures like overall survival and response rates. Participants are assigned to one of three groups one receiving 5 mgkg TRK-950 plus ramucirumab and paclitaxel, another receiving 10 mgkg TRK-950 plus the same drugs, and a third group receiving ramucirumab and paclitaxel alone. Treatments are given intravenously following a 28-day cycle schedule, with specific dosing days for each drug. The study compares these groups to find the optimal dose and monitor drug interactions and immune responses. During the trial, participants will have regular assessments including scans, clinical evaluations, and laboratory tests to monitor disease progression and side effects. Researchers will track pharmacokinetics, antibody development, and quality of life using questionnaires throughout the study, which may last up to about 24 months. Safety monitoring will continue for 45 days after the last study dose, ensuring close follow-up for any adverse events or treatment effects.
CONDITIONS
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
(
(Asia sites)Toray Contact for Clinical Trial Information
(
(US sites) Contact for Clinical Trial Information
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Toray Industries, Inc
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | TRK-950 5 mg/kg combination | TRK-950 10 mg/kg combination | Ramucirumab + Paclitaxel |
|---|---|---|---|
| What is it? | A combination of TRK-950 at 5 mg/kg plus ramucirumab and paclitaxel, all given by intravenous infusion, tested as a potential treatment for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. | A combination of TRK-950 at 10 mg/kg plus ramucirumab and paclitaxel, all given by intravenous infusion, evaluated for the same patient population. | Ramucirumab plus paclitaxel both given by intravenous infusion, an established combination treatment for advanced gastric or GEJ adenocarcinoma after prior therapy. |
| Role in the trial | Investigational treatment arm evaluating the lower dose of TRK-950 added to the standard regimen. | Investigational treatment arm evaluating the higher dose of TRK-950 with the same backbone regimen. | Active control arm representing the established standard second-line chemotherapy regimen. |
| Primary use | Studied as a second-line treatment option for adults with progressive or metastatic gastric or GEJ adenocarcinoma who meet eligibility criteria. | Also studied as a second-line treatment for eligible adults with advanced or metastatic gastric or GEJ adenocarcinoma. | Recognized as the preferred second-line treatment for patients with gastric or GEJ adenocarcinoma who have progressed after first-line therapy. |
| How is it given? | TRK-950 at 5 mg/kg administered by intravenous infusion over 60 minutes on Days 1, 8, 15, and 21 of each 28-day cycle, together with ramucirumab and paclitaxel on their respective standard schedules. | TRK-950 at 10 mg/kg administered by intravenous infusion on the same schedule, along with ramucirumab and paclitaxel according to their established dosing regimen. | Ramucirumab 8 mg/kg intravenously on Days 1 and 15 and paclitaxel 80 mg/m² intravenously on Days 1, 8, and 15 of each 28-day cycle. |
| Evidence status | Efficacy and safety are being evaluated in this randomized trial; published evidence for TRK-950 in gastric cancer to date is limited to early-phase studies with small numbers of patients. | Effectiveness and safety are also under investigation in this trial; no established published evidence exists for this dose in gastric cancer. | Established second-line therapy based on multiple randomized trials, with proven survival and response benefits for advanced gastric or GEJ adenocarcinoma after first-line therapy. |
| Important limitations | Long-term safety and efficacy data of TRK-950 combined with ramucirumab and paclitaxel are not yet known; results are pending trial outcomes. | The true benefit and risk profile of TRK-950 at this dose in combination with standard therapy is not yet established and depends on the completion of the study. | Risks include known adverse effects such as neutropenia and hypertension, which require monitoring; benefit is established in the studied population but efficacy may be limited in patients with rapidly progressive disease. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to approximately 24 months
Participants receive assigned study treatments including TRK-950 at one of two doses combined with ramucirumab and paclitaxel or ramucirumab with paclitaxel alone, given in 28-day cycles with specific dosing days.
Dosing on Days 1, 8, 15, and 22 of each 28-day cycle
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Takafumi Koyama, Kan Yonemori, Jun Sato...
https://pubmed.ncbi.nlm.nih.gov/41979863/Toray Industries, Inc
Lead Sponsor